Paolo Pigini

Paolo Pigini

Auto-generated profile, based on publicly available information

Paolo Pigini

Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Open access
SGSamuele Gherardi
Samuele Gherardi
MBMatteo Bovolenta
Matteo Bovolenta
CPChiara Passarelli
Chiara Passarelli
MFMaria Sofia Falzarano
Maria Sofia Falzarano
PPPaolo Pigini
Paolo Pigini
GPGiovanni Perini
Giovanni Perini
The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus. It spans 2.2Mb and accounts for approximately 0,1% of the entire human genome. Mutations in this gene cause Duchenne and Becker Muscular Dystrophy, X-linked Dilated Cardiomyopathy, and other milder muscle phenotypes. Beside the remarkable number of reports describing dystrophin gene expression and the pathogenic consequences of the gene mutations in dystrophinopathies, the full scenario of the DMD transcription dynamics remains however, poorly understood. Considering that the full transcription of the DMD gene requires about 16h, we have investigated the activity of RNA Polymerase II along the entire DMD locus within the context of specific chromatin modifications using a variety of chromatin-based techniques. Our results unveil a surprisingly powerful processivity of the RNA polymerase II along the entire 2.2Mb of the DMD locus with just one site of pausing around intron 52. We also discovered epigenetic marks highlighting the existence of four novel cis‑DNA elements, two of which, located within intron 34 and exon 45, appear to govern the architecture of the DMD chromatin with implications on the expression levels of the muscle dystrophin mRNA. Overall, our findings provide a global view on how the entire DMD locus is dynamically transcribed by the RNA pol II and shed light on the mechanisms involved in dystrophin gene expression control, which can positively impact on the optimization of the novel ongoing therapeutic strategies for dystrophinopathies.

1 March 2018 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
FFFerrucci Francesco
Ferrucci Francesco
RCRoberto Ciaccio
Roberto Ciaccio
SMSara Monticelli
Sara Monticelli
PPPaolo Pigini
Paolo Pigini
SGSimone Di Giacomo
Simone Di Giacomo
GPGiovanni Perini
Giovanni Perini

27 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
PPPaolo Pigini
Paolo Pigini
HXHuilin Xu
Huilin Xu
YJYan Ji
Yan Ji
HLHannah Lindmeier
Hannah Lindmeier
HSHenry R Saltzman
Henry R Saltzman
EMElisabetta Morini
Elisabetta Morini
Background: Poison exons (PE) are highly conserved exons whose inclusion creates premature termination codons (PTCs) and triggers nonsense-mediated decay (NMD) of the mature transcript. Despite their important role in post-transcriptional regulation, PEs remain poorly annotated due to the lack of systematic transcriptome-wide approaches. Results: A comparative analysis of 957 eukaryotic transcriptomes revealed that Homo Sapiens exhibits the highest enrichment of NMD-targeted isoforms. By systematically predicting and annotating splicing events that generate PTCs, we found 9,814 PEs in the human genome. Using RNA-seq dataset from GTEx and BrainSpan, we analyzed PE splicing across tissues and developmental stages and identified 83 PEs uniquely found in the human brain, 973 PEs with brain-specific differential splicing, and 1,284 PEs differentially spliced during brain development. By integrating ClinVar variant annotations with SpliceAI predictions, we identified 1,625 pathogenic variants associated with neurological disorders that are predicted to affect the splicing of 743 PEs, and we functionally validated the impact of a subset of them using CRISPR prime-editing in human cells. Functional characterization of the deep intronic NDUFAF6 c.420+784C>T variant associated with Leigh syndrome demonstrated increased PE inclusion and a significant reduction in NDUFAF6 protein levels in iPSC-derived induced neurons. Mutant cells also exhibited impaired mitochondrial membrane potential compared to controls. Together, these findings provide functional evidence that the c.420+784C>T variant promotes aberrant PE inclusion, leading to reduced NDUFAF6 expression and mitochondrial dysfunction. Conclusions: Our findings highlight PEs as pivotal regulators of gene expression in the human brain and support the therapeutic targeting of PE splicing in neurological diseases.

19 August 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
MSM. Catarina Silva
M. Catarina Silva
HLHannah Lindmeier
Hannah Lindmeier
PPPaolo Pigini
Paolo Pigini
JLJennifer Laughlin
Jennifer Laughlin
YYYong Yu
Yong Yu
EMElisabetta Morini
Elisabetta Morini
Tauopathies are neurodegenerative diseases characterized by the pathological accumulation of microtubule-associated protein tau (MAPT) in the brain. These disorders, like frontotemporal dementia (FTD-tau), currently lack effective therapies and can occur sporadically or be inherited when associated with MAPT gene mutations. Exon 10 and adjacent introns of the MAPT gene are a hotspot for pathogenic variants, including splicing mutations that enhance exon 10 inclusion and increase 4R tau expression and 4R-specific gain-of-function mutations that generate aggregation-prone tau. For these 4R tauopathies, a targeted messenger RNA (mRNA) splicing approach that promotes exon 10 exclusion may offer therapeutic benefit. We have developed splicing modulator compounds (SMCs) that promote MAPT exon 10 exclusion and demonstrated their efficacy in neurons derived from patients with FTD carrying the tau Pro 301 →Leu (P301L) gain-of-function mutation or the tau Ser 305 →Asn (S305N) splicing mutation. Treatment with SMC reduced 4R tau expression and decreased the accumulation of hyperphosphorylated tau (pTau) and oligomeric and insoluble tau proteoforms, thereby rescuing tau-associated neuronal toxicity. A lead SMC corrected the 3R/4R splice ratio in vivo and reduced pTau in the brain of a human gene-replacement mouse model expressing the tau Asn 279 →Lys (N279K) splicing mutation. These findings support the therapeutic potential of this class of small molecules and establish MAPT pre-mRNA splicing modulation as a promising strategy for the treatment of 4R tauopathies.

12 November 2026 in Neurology Genetics
Verified
Journal Article
Closed access
HKHoracio Kaufmann
Horacio Kaufmann
ADAlejandra González Duarte
Alejandra González Duarte
KDKaia Dalamo
Kaia Dalamo
ABAndreana Barnett
Andreana Barnett
PVPatricio Millar Vernetti
Patricio Millar Vernetti
SSSusan A. Slaugenhaupt
Susan A. Slaugenhaupt